World’s first CDK2/4/6 inhibitor approved in China
The world’s first CDK2/4/6 inhibitor, developed by Chia Tai Tianqing Pharmaceutical Group, a subsidiary of Sino Biopharmaceutical, was officially approved for market launch on Thursday. CDK2/4/6 inhibitors are targeted cancer drugs that stop certain proteins (CDK2, CDK4, and CDK6) that cancer cells need to grow and divide. Breast cancer has become the most common cancer…









